Humacyte, Inc. Operating Income
Humacyte, Inc. (HUMA) reported Operating Income of -$27.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Humacyte, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$27.00M.
- Humacyte, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$28.93M.
- Humacyte, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$30.84M.
- Humacyte, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$24.39M.
- Humacyte, Inc. operating income (loss) for fiscal 2025 was -$108.14M.
- Humacyte, Inc. operating income (loss) for fiscal 2024 was -$114.40M.
- Humacyte, Inc. operating income (loss) for fiscal 2023 was -$100.05M.
- Humacyte, Inc. operating income (loss) for fiscal 2022 was -$84.58M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$27.00M 10-Q · filed 2026-08-12 | -$55.93M 10-Q · filed 2026-08-12 | -$86.77M derived: sum of 3 quarters · filed 2026-08-12 | -$111.16M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$28.93M 10-Q · filed 2026-05-13 | -$59.77M derived: sum of 2 quarters · filed 2026-05-13 | -$84.16M derived: sum of 3 quarters · filed 2026-05-13 | -$113.89M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$30.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$55.23M derived: sum of 2 quarters · filed 2026-03-27 | -$84.95M derived: sum of 3 quarters · filed 2026-08-12 | -$108.14M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$24.39M 10-Q · filed 2025-11-12 | -$54.12M derived: sum of 2 quarters · filed 2026-08-12 | -$77.30M 10-Q · filed 2025-11-12 | -$105.39M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$29.73M 10-Q · filed 2026-08-12 | -$52.91M 10-Q · filed 2026-08-12 | -$81.00M derived: sum of 3 quarters · filed 2026-08-12 | -$111.23M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$23.18M 10-Q · filed 2026-05-13 | -$51.27M derived: sum of 2 quarters · filed 2026-05-13 | -$81.50M derived: sum of 3 quarters · filed 2026-05-13 | -$111.00M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$28.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$58.32M derived: sum of 2 quarters · filed 2026-03-27 | -$87.82M derived: sum of 3 quarters · filed 2026-03-27 | -$114.40M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$30.23M 10-Q · filed 2025-11-12 | -$59.73M derived: sum of 2 quarters · filed 2025-11-12 | -$86.31M 10-Q · filed 2025-11-12 | -$112.49M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$29.50M 10-Q · filed 2025-08-11 | -$56.08M 10-Q · filed 2025-08-11 | -$82.26M derived: sum of 3 quarters · filed 2025-08-11 | -$106.88M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | -$26.58M 10-Q · filed 2025-05-13 | -$52.76M derived: sum of 2 quarters · filed 2025-05-13 | -$77.38M derived: sum of 3 quarters · filed 2025-05-13 | -$104.11M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$26.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$50.80M derived: sum of 2 quarters · filed 2025-03-31 | -$77.53M derived: sum of 3 quarters · filed 2025-03-31 | -$100.05M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$24.62M 10-Q · filed 2024-11-08 | -$51.35M derived: sum of 2 quarters · filed 2024-11-08 | -$73.86M 10-Q · filed 2024-11-08 | -$94.66M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | -$26.73M 10-Q · filed 2024-08-13 | -$49.24M 10-Q · filed 2024-08-13 | -$70.03M derived: sum of 3 quarters · filed 2024-08-13 | -$93.53M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$22.51M 10-Q · filed 2024-05-13 | -$43.30M derived: sum of 2 quarters · filed 2024-05-13 | -$66.80M derived: sum of 3 quarters · filed 2024-05-13 | -$85.33M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$20.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$44.28M derived: sum of 2 quarters · filed 2024-03-28 | -$62.81M derived: sum of 3 quarters · filed 2024-03-28 | -$84.58M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$23.49M 10-Q · filed 2023-11-09 | -$42.02M derived: sum of 2 quarters · filed 2023-11-09 | -$63.79M 10-Q · filed 2023-11-09 | -$85.42M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$18.53M 10-Q · filed 2023-08-14 | -$40.29M 10-Q · filed 2023-08-14 | -$61.92M derived: sum of 3 quarters · filed 2023-08-14 | -$82.46M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$21.76M 10-Q · filed 2023-05-12 | -$43.39M derived: sum of 2 quarters · filed 2023-05-12 | -$63.93M derived: sum of 3 quarters · filed 2023-05-12 | -$83.20M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | -$21.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$42.17M derived: sum of 2 quarters · filed 2023-03-24 | -$61.44M derived: sum of 3 quarters · filed 2023-03-24 | -$81.21M 10-K · filed 2023-03-24 | ||
| 2021-09-30 | -$20.54M 10-Q · filed 2022-11-10 | -$39.81M derived: sum of 2 quarters · filed 2022-11-10 | -$59.58M 10-Q · filed 2022-11-10 | -$42.62M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$19.27M 10-Q · filed 2022-08-12 | -$243.67K 10-Q · filed 2021-08-16 | -$39.04M 10-Q · filed 2022-08-12 | -$737.49K 10-Q · filed 2021-08-16 | -$22.07M derived: sum of 3 quarters · filed 2022-08-12 | -$39.29M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$19.77M 10-Q · filed 2022-05-13 | -$493.82K 10-Q · filed 2021-05-17 | -$2.81M derived: sum of 2 quarters · filed 2022-05-13 | -$20.02M derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $16.96M derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | -$249.52K 10-K/A · filed 2021-05-14 | -$64.60M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | -$17.21M 10-Q · filed 2021-11-15 | -$18.77K 10-Q · filed 2020-11-13 | -$48.93M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |